Last reviewed · How we verify
antimuscarinic medication
At a glance
| Generic name | antimuscarinic medication |
|---|---|
| Also known as | Ditropan XL, Gelnique, Enablex, Trosec, Sanctura |
| Sponsor | Astellas Scientific & Medical Affairs, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial (NA)
- TReating Incontinence for Underlying Mental and Physical Health (PHASE4)
- Boosting Referrals to Asthma Specialists for Patients Seen at the Emergency Room for an Asthma Exacerbation (NA)
- Sublingual Atropine Bioequivalence by Route of Administration (SABER) (PHASE1)
- Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia (NA)
- 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (PHASE4)
- Revefenacin in Acute Respiratory Insufficiency in COPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- antimuscarinic medication CI brief — competitive landscape report
- antimuscarinic medication updates RSS · CI watch RSS
- Astellas Scientific & Medical Affairs, Inc. portfolio CI